Table 1 Demographic and clinical data
From: Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients
Variables | N (%) | Variables | N (%) |
|---|---|---|---|
Gender | Major surgery | ||
 Female | 40 (57.1) | No | 60 (85.7) |
 Male | 30 (42.9) | Yes | 10 (14.3) |
Habits | Minor surgery | ||
 Smokers | 18 (25.7) | No | 40 (57.1) |
 Non-smokers | 52 (74.3) | Yes | 30 (42.9) |
History of bilharziasis | Hazardous injection | ||
 No | 37 (52.9) | No | 56 (80) |
 Yes | 33 (47.1) | Yes | 14 (20) |
Oral treatment (bilharziasis) | Diabetes | ||
 No | 44 (62.9) | No | 50 (71.4) |
 Yes | 26 (37.1) | Yes | 20 (28.6) |
Parenteral treatment (bilharziasis) | HTN | ||
 No | 61 (87.1) | No | 48 (68.6) |
 Yes | 9 (12.9) | Yes | 22 (31.4) |
Dental manipulations | Dyslipidemia | ||
 No | 30 (42.9) | No | 60 (85.7) |
 Yes | 40 (57.1) | Yes | 10 (14.3) |
Blood transfusion | Hepatomegaly | ||
 No | 59 (84.3) | No | 36 (51.4) |
 Yes | 11 (15.7) | Yes | 34 (48.6) |
Metabolic syndrome | |||
 No | 45 (64.3) |  |  |
 Yes | 25 (35.7) |  |  |